Austin Heart, a provider of cardiac and vascular services, has started enrolling peripheral arterial disease (PAD) patients for Avinger's Connect II trial.
The multi-center, non-randomized and prospective trial is designed to evaluate Ocelot on 100 PAD patients with femoropopliteal CTO lesions at 17 sites, including three in the EU.
Austin Heart's interventional cardiologists who are participating in the Connect II trial will use Ocelot to help restore blood flow in completely blocked arteries in patients' legs through a simple two-millimeter skin incision.
Ocelot will also be used by cardiologists to help eliminate the need for bypass surgeries and/or amputations in patients with the disease.
Study national principle investigator Matthew Selmon said, "The trial is hoping to help patients regain mobility and improve quality of life, and in the process many patients might be spared unnecessary amputations."
